There was no correlation between responses or prolonged SD with mutations activating the PI3K pathway, although 1 metastatic breast cancer patient harboring a PIK3CA mutation (exon 20), previously treated with 3 lines of chemotherapy and 1 line of hormonal therapy with progressive disease, demonstrated SD for 4 months. The gene discussed is PIK3CA; the disease is breast carcinoma.